Plasmapheresis, CMV hyperimmune globulin, and anti-CD20 allow ABO-incompatible renal transplantation without splenectomy. - Wikidata - wikimedia - TriplyDB

Plasmapheresis, CMV hyperimmune globulin, and anti-CD20 allow ABO-incompatible renal transplantation without splenectomy.

Plasmapheresis, CMV hyperimmune globulin, and anti-CD20 allow ABO-incompatible renal transplantation without splenectomy.

http://www.wikidata.org/entity/Q44989312

about

Modern approaches to incompatible kidney transplantation Rituximab in renal transplantation Plasmapheresis in immunologic renal disease ABO incompatible kidney transplantation - an analysis of UNOS Registry data.Rituximab, an anti-cd20 monoclonal antibody: history and mechanism of action.Baseline Anti-blood Group Antibody Titers and their Response to Desensitization and Kidney Transplantation.Emerging Role of the Spleen in the Pharmacokinetics of Monoclonal Antibodies, Nanoparticles and Exosomes.The generation and maintenance of serum alloantibody.Donor exchange programs in kidney transplantation: rationale and operational details from the north central donor exchange cooperative.A case of nearly mistaken AB para-Bombay blood group donor transplanted to a group 'O' recipient.Accommodation in renal transplantation: unanswered questions.Strategies to increase the donor pool and access to kidney transplantation: an international perspective Early clinical complications after ABO-incompatible live-donor kidney transplantation: a national study of Medicare-insured recipients.ABO Incompatible Kidney Transplantation-Current Status and Uncertainties.Preformed antibody, not primed T cells, is the initial and major barrier to bone marrow engraftment in allosensitized recipients Infectious complications in kidney-transplant recipients desensitized with rituximab and intravenous immunoglobulin.Intravenous immunoglobulins in liver transplant patients: Perspectives of clinical immune modulation.Outcomes of ABO-incompatible kidney transplantation in the United States.Synthetic blood group antigens for anti-A removal device and their interaction with monoclonal anti-A IgM.Infectious risks and optimal strength of maintenance immunosuppressants in rituximab-treated kidney transplantation ABO-incompatible living donor kidney transplantation without post-transplant therapeutic plasma exchange.Incidence and outcomes of BK virus allograft nephropathy among ABO- and HLA-incompatible kidney transplant recipients Characteristics of protein-carbohydrate interactions as a basis for developing novel carbohydrate-based antirejection therapies.Transplantation across previously incompatible immunological barriers.The emerging role of rituximab in organ transplantation.The utility of splenectomy as rescue treatment for severe acute antibody mediated rejection.Economic Impacts of ABO-Incompatible Live Donor Kidney Transplantation: A National Study of Medicare-Insured Recipients Successful renal transplantation with desensitization in highly sensitized patients: a single center experience.ABO-incompatible living-donor pediatric kidney transplantation in Japan.The Effect of Histological CD20-Positive B Cell Infiltration in Acute Cellular Rejection on Kidney Transplant Allograft Survival.ABO blood group incompatibility: a diminishing barrier to successful kidney transplantation?Benefits and limitations of plasmapheresis in renal diseases: an evidence-based approach.Segmental live donor pancreas transplantation: review and critique of rationale, outcomes, and current recommendations.Immunohaematological and apheretic aspects of the first kidney transplant from a living, ABO-incompatible donor carried out in Italy.Update on the role of rituximab in kidney diseases and transplant.Molecular deciphering of the ABO system as a basis for novel diagnostics and therapeutics in ABO incompatible transplantation.An update on ABO-incompatible kidney transplantation.Historical perspectives in kidney transplantation: an updated review.Determination of rituximab dose according to immunologic risk in ABO-incompatible kidney transplantation.Strategies to overcome the ABO barrier in kidney transplantation.

P2860

Q27010224-752D2A03-227D-442F-8950-A764A8317910 Q27026434-7A9237F9-2466-48F3-92C6-473811368140 Q27027106-B9C8CFC1-DE41-42B7-A5FF-EC17164D9520 Q31034921-0A1E88ED-E85A-426F-BC7A-098E7C2F2527 Q33370836-24BCB739-C6F9-461C-9EDD-401DFF21A673 Q33697381-31750C33-E1AA-442C-821C-439D7B60137C Q33838871-10778AC8-4A4D-4504-9415-BCF04DA35E2A Q34106158-A5C69010-445B-46FE-B8C5-F99460AFA0EC Q34307267-7804E619-7667-4B73-9AA6-A26C6A2E0C6D Q34439147-C43C2595-D509-4698-B004-2B7CD74D7858 Q34903473-92EF8220-79E7-4A1F-9598-EF284A2435F0 Q35022239-6307E982-2B31-4374-8CEB-04A4E7E98FEB Q35543289-5EB13C13-EACE-4FC2-B6D5-A86F14912566 Q35607565-F992C787-8A6D-47C7-8633-FFEF48700FE9 Q35616055-8E45FE9D-0D13-4B85-A1C0-ECFE8952BBC9 Q35664634-73497B10-8D17-43A9-BBBA-6FA6E5201BF8 Q35715908-50AEB184-1338-4C3E-973C-332532B8485E Q35822937-BF1A6630-5A3B-4532-894C-40409E72B4E1 Q35925181-0288C7EC-C2CA-4AC5-89FA-7E94B8487A90 Q35953320-546604EA-44F6-44D5-8960-40BB6385DF27 Q36031039-263333FE-C159-445D-9635-41BCA15A6677 Q36126901-4D95216C-6410-4531-AFCB-45CF1493E6E7 Q36304925-19DC0837-4087-4930-B570-C5F4DEC61958 Q36379447-41E2B13B-32EF-4802-9733-E5A95440BE35 Q36530278-BF1A403E-D865-4F9B-A914-CA19A029DC12 Q36772871-E1CB7F83-3582-4119-BD69-1DE7F7D67662 Q36835081-E5D4C712-CB5D-4E50-BE07-89665095C4B9 Q37078119-65F40957-81FC-4355-832B-DBC3D9C7F822 Q37446876-97B63D58-3C42-428B-B415-193E857D731A Q37531824-827F86B7-E3E7-48A1-83B0-C84AD074B4C9 Q37803412-B94E36F0-ADA0-4717-BD30-C0AF7E0C3EBF Q37820338-2C760302-897E-4739-BDF5-36F2406EA507 Q37821062-21D613B7-ECC3-4594-9160-13B8742026EA Q37830813-FCD1BF7A-C9BC-40EC-B155-CBA45FC800D8 Q37970443-3DDB8221-D046-4D22-AD56-CEDEFB1935CB Q38172280-EEB90BE2-BE42-458E-B0E1-EB686C1C5235 Q38267202-9098EED2-8894-4817-BE7E-DBEC66EAF586 Q38373018-111EE76E-1508-4A90-AF3F-452D4C097988 Q38460398-590FF483-30BA-4F66-BDEA-DA27E0F13F09 Q38577657-E31F50E7-561E-4083-B859-1DA332989902

P2860

Plasmapheresis, CMV hyperimmune globulin, and anti-CD20 allow ABO-incompatible renal transplantation without splenectomy.

http://www.wikidata.org/entity/Q44989312

description

2004 nî lūn-bûn

@nan

2004年の論文

@ja

2004年学术文章

@wuu

2004年学术文章

@zh-cn

2004年学术文章

@zh-hans

2004年学术文章

@zh-my

2004年学术文章

@zh-sg

2004年學術文章

@yue

2004年學術文章

@zh

2004年學術文章

@zh-hant

name

Plasmapheresis, CMV hyperimmun ...... lantation without splenectomy.

@en

Plasmapheresis, CMV hyperimmun ...... lantation without splenectomy.

@nl

type

label

Plasmapheresis, CMV hyperimmun ...... lantation without splenectomy.

@en

Plasmapheresis, CMV hyperimmun ...... lantation without splenectomy.

@nl

prefLabel

Plasmapheresis, CMV hyperimmun ...... lantation without splenectomy.

@en

Plasmapheresis, CMV hyperimmun ...... lantation without splenectomy.

@nl

P1433

Q44989312-F60CDD0C-6901-4231-8010-6FCB9306CEA2

P1476

Q44989312-B886239E-825F-4DDE-A3F2-A4063EB25CCF

P2093

Q44989312-1AE2BE85-E11E-459C-9AED-0CEA44D82CC3

Q44989312-4F1B163D-7D90-47AD-AC99-EFEF2748A83B

Q44989312-80559D2F-9AFE-442F-BC62-6A9454770D68

Q44989312-856F9966-E95C-4758-910C-A18B75A93160

Q44989312-A9643266-188F-41FB-93CC-7ADECD6A0B0D

Q44989312-BEECD1AE-4C40-4A2E-AF1B-1786058F1E04

Q44989312-D8790CC8-7600-4EF3-A93A-7F80BDE4EB05

Q44989312-E7BE95AB-7389-4836-BB2F-0B7945EE4A61

Q44989312-F2EC63ED-7584-4F5D-87F5-13E61567AF49

P2860

Q44989312-101893EB-99B0-42A7-9AE9-A9444D7AFB09

Q44989312-171AC8D7-E3F2-45D8-96B5-F597D2DD5A96

Q44989312-3FB464AD-ADDA-4BC5-BA0B-FAA87E270460

Q44989312-581826AC-40BB-4903-85E8-29FD4169E222

Q44989312-C530FFB9-BF7F-46A5-B8E2-8DF480109873

P304

Q44989312-414A2249-9C84-468C-B0D2-C6264D9DDAE4

P31

Q44989312-182BAC5B-2586-45CA-8A9E-B3EF7DFFCE1B

P356

Q44989312-5C803977-DAA4-419F-A10B-E05093D641A5

P407

Q44989312-A6A99BC4-EBA0-43FD-8FB7-09A814E29BF6

P433

Q44989312-358BD8C3-6B39-426A-91D7-1BD9B065020E

P478

Q44989312-54D6DA26-71C8-4C3B-A4AB-0A4DF5066C98

P577

Q44989312-85128995-1095-4A58-9310-B87C0D12E018

P5875

Q44989312-52CE8D7E-4BFE-436E-BD8B-E4A36EABB7A7

P698

Q44989312-E08E8E28-C493-4A47-9FCD-B2BFC68015DB

P356

J.1600-6143.2004.00507.X

P1433

American Journal of Transplantation

P1476

Plasmapheresis, CMV hyperimmun ...... lantation without splenectomy.

@en

P2093

Christopher E Simpkins

http://www.w3.org/2001/XMLSchema#string

Christopher J Sonnenday

http://www.w3.org/2001/XMLSchema#string

Daniel S Warren

http://www.w3.org/2001/XMLSchema#string

Karen E King

http://www.w3.org/2001/XMLSchema#string

Mark Haas

http://www.w3.org/2001/XMLSchema#string

Mathew Cooper

http://www.w3.org/2001/XMLSchema#string

Milagros Samaniego

http://www.w3.org/2001/XMLSchema#string

R Sue Shirey

http://www.w3.org/2001/XMLSchema#string

Robert A Montgomery

http://www.w3.org/2001/XMLSchema#string

P2860

ABO-incompatible kidney transplantation using both A2 and non-A2 living donors.

Successful A1-to-O ABO-incompatible kidney transplantation after a preconditioning regimen consisting of anti-CD20 monoclonal antibody infusions, splenectomy, and double-filtration plasmapheresis.

Successful ABO-incompatible kidney transplantations without splenectomy using antigen-specific immunoadsorption and rituximab.

Plasmapheresis and intravenous immune globulin provides effective rescue therapy for refractory humoral rejection and allows kidneys to be successfully transplanted into cross-match-positive recipients.

The Banff 97 working classification of renal allograft pathology

P304

1315-1322

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/J.1600-6143.2004.00507.X

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

4

http://www.w3.org/2001/XMLSchema#string

P577

2004-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

8440305

http://www.w3.org/2001/XMLSchema#string

P698

15268734

http://www.w3.org/2001/XMLSchema#string